Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 trial of oral MRX-1 to treat complicated skin and skin structure infections (cSSSI) in China

Trial Profile

A Phase 3 trial of oral MRX-1 to treat complicated skin and skin structure infections (cSSSI) in China

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Contezolid (Primary) ; Linezolid
  • Indications Bacterial infections; Skin and soft tissue infections
  • Focus Registrational; Therapeutic Use
  • Sponsors MicuRx Pharmaceuticals
  • Most Recent Events

    • 03 Jun 2021 According to a MicuRx Pharmaceuticals media release, the China National Medical Products Administration (NMPA) has approved new drug application for contezolid as the treatment of complicated skin and soft tissue infection, based on data from this trial.
    • 19 Sep 2019 Primary endpoint (Noninferiority compared to linezolid for the Clinical cure rate at the test-of-cure visit (TOC visit, 7-14 days after the last dose of study drug)) has been met, according to the MicuRx Pharmaceuticals media release.
    • 19 Sep 2019 According to a MicuRx media release, the company plan to file a New Drug Application with the National Medical Products Administration (NMPA) of China in the 4th quarter of 2019.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top